Scarica l'app Stockscreener
25.88
2.52%
-0.67
Dopo l'orario di chiusura:
25.88
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira (PCRX) Joins Global Effort to Enhance Osteoarthritis Rese - GuruFocus
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care - GlobeNewswire
How risky is Pacira BioSciences Inc. stock nowWeekly Trend Summary & Free High Return Stock Watch Alerts - Улправда
Pacira BioSciences (PCRX): Reassessing Valuation After a 45% Year‑to‑Date Share Price Rally - Yahoo Finance
Pacira BioSciences stock earns technical rating upgrade - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences (PCRX) Is Up 7.7% After Positive Spine Pain Pilot Data and New FDA ClearanceHas The Bull Case Changed? - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares - MarketBeat
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock - MarketBeat
Pacira Biosciences CFO cross sells $626k in shares By Investing.com - Investing.com India
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
Natixis Buys 151,250 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
(PCRX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Pacira BioSciences (NASDAQ:PCRX) Upgraded to Hold at Barclays - MarketBeat
Russell Investments Group Ltd. Sells 5,703,634 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Barclays Initiates Coverage of Pacira BioSciences (PCRX) with Equal-Weight Recommendation - Nasdaq
Pacira BioSciences (PCRX): Barclays Initiates Coverage with Equa - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays - MarketBeat
102,668 Shares in Pacira BioSciences, Inc. $PCRX Bought by WINTON GROUP Ltd - MarketBeat
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
EV Market: Will Pacira BioSciences Inc. stock maintain momentum in 20252025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Will Pacira BioSciences Inc. (82P) stock rise with strong economyQuarterly Trade Report & Real-Time Volume Analysis Alerts - Newser
How Investors Are Reacting To Pacira BioSciences (PCRX) Spine Pain Trial Win And New FDA Clearance - Sahm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Can Pacira BioSciences Inc. (82P) stock surprise with quarterly resultsJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Is Pacira BioSciences Inc. (82P) stock among top earnings plays2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
Can Pacira BioSciences Inc. stock deliver surprise earnings beatWeekly Market Summary & Real-Time Price Movement Reports - Newser
Pacira Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Pacira’s iovera° shows better outcomes than RFA for chronic back pain By Investing.com - Investing.com South Africa
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira’s iovera° shows better outcomes than RFA for chronic back pain - Investing.com Nigeria
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Ortho Spine News
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain - marketscreener.com
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
American Century Companies Inc. Has $28.26 Million Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
(PCRX) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation in Focus Following Moves to Defend EXPAREL Patents Against Generic Competition - Sahm
Pacira down after FDA filing for generic Exparel - MSN
Pacira BioSciences (PCRX): Assessing Valuation Following Legal Win That Delays EXPAREL Generic Approvals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
12.55%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):